利拉鲁肽对2型糖尿病合并高血压患者血糖、血压及血脂的影响

发布时间：2018-02-12 12:54

本文关键词： 型糖尿病高血压利拉鲁肽血糖血压血脂　出处：《山东医药》2017年21期 　论文类型：期刊论文

【摘要】：目的探讨利拉鲁肽对2型糖尿病合并高血压患者血糖、血压及血脂的影响。方法选取2型糖尿病合并高血压患者120例,随机分为观察组与对照组各60例。观察组给予利拉鲁肽治疗,起始剂量为0.6 mg/d皮下注射,1周后增加剂量至1.2 mg/d,若随机血糖11.1 mmol/L或空腹血糖7.0 mmol/L,2周后增至1.8 mg/d。对照组给予胰岛素治疗,根据患者情况每天多次皮下注射。两组均治疗12周。分别于治疗前及治疗后当日测量血糖、血压、血脂。结果治疗后两组空腹血糖、糖化血红蛋白、空腹胰岛素、胰岛素抵抗指数、收缩压、舒张压、总胆固醇、甘油三酯、高密度脂蛋白、低密度脂蛋白与治疗前比较,P均0.05;治疗后观察组以上指标与对照组比较,P均0.05。结论利拉鲁肽能有效控制2型糖尿病合并高血压患者的血糖水平,降低血压和血脂。
[Abstract]:Objective to investigate the effects of liraud on blood glucose, blood pressure and blood lipid in patients with type 2 diabetes mellitus complicated with hypertension. Methods 120 patients with type 2 diabetes complicated with hypertension were selected. They were randomly divided into observation group (n = 60) and control group (n = 60). The initial dose of 0.6 mg/d was increased to 1.2 mg / d one week after subcutaneous injection, and if the random glucose was 11.1 mmol/L or fasting glucose was 7.0 mmol / L ~ (-1) after 2 weeks, it was increased to 1.8 mg / d. The control group was treated with insulin. Blood glucose, blood pressure, blood lipids were measured before and after treatment for 12 weeks. Results fasting blood glucose, glycosylated hemoglobin, fasting insulin were measured in the two groups after treatment. Insulin resistance index, systolic blood pressure, diastolic blood pressure, total cholesterol, triglyceride, high density lipoprotein, Low density lipoprotein (LDL) was significantly higher than that of control group (P < 0.05). Conclusion Lilaru peptide can effectively control blood glucose level and decrease blood pressure and blood lipid in patients with type 2 diabetes mellitus complicated with hypertension.
【作者单位】：天津市滨海新区汉沽中医医院;天津医科大学第二医院;
【分类号】：R544.1;R587.1

【相似文献】